34 related articles for article (PubMed ID: 28427859)
1. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.
Gibney GT; Aziz SA; Camp RL; Conrad P; Schwartz BE; Chen CR; Kelly WK; Kluger HM
Ann Oncol; 2013 Feb; 24(2):343-349. PubMed ID: 23022995
[TBL] [Abstract][Full Text] [Related]
2. MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.
Macher-Goeppinger S; Keith M; Endris V; Penzel R; Tagscherer KE; Pahernik S; Hohenfellner M; Gardner H; Grüllich C; Schirmacher P; Roth W
Oncotarget; 2017 Jan; 8(1):1046-1057. PubMed ID: 27894094
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of ARK5 and SIRT3 expression in renal cell carcinoma and their clinical significance.
Elkady N; Aldesoky AI; Dawoud MM
Diagn Pathol; 2023 Nov; 18(1):125. PubMed ID: 37996927
[TBL] [Abstract][Full Text] [Related]
4. Expressions and Clinical Significance of Met and YAP in Gastric Cancer Tissue Microarray.
Li J; Zhang X; Liu Y; Zhou J; Shen L; Yue G
Gastroenterol Res Pract; 2024; 2024():5591298. PubMed ID: 38634107
[TBL] [Abstract][Full Text] [Related]
5. Fluid intake-to-bed time, nocturia frequency and the risk of urothelial carcinoma of the bladder: a case-control study.
Cui J; Bo Q; Zhang N; Chen S; Yu M; Wang S; Han J; Chen P; Zhang D; Zhu Y; Shi B
J Cancer; 2017; 8(16):3268-3273. PubMed ID: 29158799
[No Abstract] [Full Text] [Related]
6. Prognostic scores based on the preoperative plasma fibrinogen and serum albumin level as a prognostic factor in patients with upper urinary tract urothelial carcinoma.
Cui J; Yu M; Zhang N; Wang S; Zhu Y; Chen S; Zhu K; Du J; Zhao H; Liu X; Chen P; Wang W; Zhang D; Shi B
Oncotarget; 2017 Sep; 8(40):68964-68973. PubMed ID: 28978171
[TBL] [Abstract][Full Text] [Related]
7. Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity.
Bersanelli M; Gnetti L; Pilato FP; Varotti E; Quaini F; Campanini N; Rapacchi E; Camisa R; Carbognani P; Silini EM; Rusca M; Leonardi F; Maestroni U; Rizzo M; Brunelli M; Buti S; Ampollini L
Explor Target Antitumor Ther; 2023; 4(4):743-756. PubMed ID: 37720351
[TBL] [Abstract][Full Text] [Related]
8. Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges.
Su P; Zhang M; Kang X
Front Oncol; 2023; 13():1071030. PubMed ID: 36959792
[TBL] [Abstract][Full Text] [Related]
9. Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors.
Ma YX; Liu FR; Zhang Y; Chen Q; Chen ZQ; Liu QW; Huang Y; Yang YP; Fang WF; Xi N; Kang N; Zhuang YL; Zhang Q; Jiang YZ; Zhang L; Zhao HY
Front Immunol; 2022; 13():1024755. PubMed ID: 36341335
[TBL] [Abstract][Full Text] [Related]
10. ORP5 promotes tumor metastasis via stabilizing c-Met in renal cell carcinoma.
Song L; Zhang L; Zhou Y; Shao X; Xu Y; Pei D; Wang Q
Cell Death Discov; 2022 Apr; 8(1):219. PubMed ID: 35449154
[TBL] [Abstract][Full Text] [Related]
11. MALDI Mass Spectrometry Imaging-Prognostic Pathways and Metabolites for Renal Cell Carcinomas.
Erlmeier F; Sun N; Shen J; Feuchtinger A; Buck A; Prade VM; Kunzke T; Schraml P; Moch H; Autenrieth M; Weichert W; Hartmann A; Walch A
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406537
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review.
Kim JH; Kim BJ; Kim HS
Oncotarget; 2017 Sep; 8(43):75478-75487. PubMed ID: 29088883
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD105 cancer stem cell marker in three subtypes of renal cell carcinoma.
Saeednejad Zanjani L; Madjd Z; Abolhasani M; Shariftabrizi A; Rasti A; Asgari M
Cancer Biomark; 2018; 21(4):821-837. PubMed ID: 29286924
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of PPAR-γ and PTEN in the renal cell carcinoma.
Zhu C; Wei J; Tian X; Li Y; Li X
Int J Clin Exp Pathol; 2015; 8(10):12668-77. PubMed ID: 26722456
[TBL] [Abstract][Full Text] [Related]
15. High expression of APRIL correlates with poor prognosis in clear cell renal cell carcinoma.
Lee C; Park JW; Suh JH; Moon KC
Pathol Res Pract; 2015 Nov; 211(11):824-8. PubMed ID: 26296917
[TBL] [Abstract][Full Text] [Related]
16. Impact of tumor-associated symptoms on the prognosis of patients with renal cell carcinoma: a single-center experience of 683 patients.
Schips L; Lipsky K; Zigeuner R; Salfellner M; Winkler S; Langner C; Rehak P; Pummer K; Hubmer G
Urology; 2003 Dec; 62(6):1024-8. PubMed ID: 14665348
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of CD44 expression in renal cell carcinoma: a systematic review and meta-analysis.
Li X; Ma X; Chen L; Gu L; Zhang Y; Zhang F; Ouyang Y; Gao Y; Huang Q; Zhang X
Sci Rep; 2015 Aug; 5():13157. PubMed ID: 26287771
[TBL] [Abstract][Full Text] [Related]
18. The role of c-Met in prognosis and clinicopathology of renal cell carcinoma: Results from a single-centre study and systematic review.
Chen S; Zhu Y; Cui J; Wang Y; Xia Y; Song J; Cheng S; Zhou C; Zhang D; Zhang B; Shi B
Urol Oncol; 2017 Aug; 35(8):532.e15-532.e23. PubMed ID: 28427859
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
